Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues

Hematology/Oncology Clinics of North America

Volumn 21, Issue 3, 2007, Pages 561-573

  Kwekkeboom, Dik J ^a   Teunissen, Jaap J M ^a   Kam, Boen L ^a   Valkema, Roelf ^a   de Herder, Wouter W ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CAPECITABINE; FLUOROURACIL; INDIUM 111; OCTREOTATE; OCTREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HAIR LOSS; HUMAN; ISOTOPE LABELING; KIDNEY FAILURE; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR REGRESSION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; OCTREOTIDE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 34249704051     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.04.009     Document Type: Review

References (39)

1. Arnold R., Benning R., Neuhaus C., et al. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54 Suppl 1 (1993) 72-75
2. Janson E.T., and Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32 (1993) 225-229
3. Ducreux M., Ruszniewski P., Chayvialle J.A., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276-3281
4. 111In-DTPA°]Octreotide: the Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
5. Anthony L.B., Woltering E.A., Espanan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
6. Otte A., Herrmann R., Heppeler A., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26 (1999) 1439-1447
7. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12 (2001) 941-945
8. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43 (2002) 617-620
9. Waldherr C., Schumacher T., Maecke H.R., et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?. [abstract]. Eur J Nucl Med Mol Imaging 29 Suppl 1 (2002) S100
10. Chinol M., Bodei L., Cremonesi M., et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 32 (2002) 141-147
11. Paganelli G., Bodei L., Handkiewicz Junak D., et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66 (2002) 393-398
12. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 30 (2003) 207-216
13. Valkema R., Pauwels S., Kvols L., et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3]octreotide in patients with somatostatin receptor positive tumours. [abstract]. Eur J Nucl Med Mol Imaging 30 Suppl 2 (2003) S232
14. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 44 (2003) 1556-1560
15. De Jong M., Breeman W.A., Bakker W.H., et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58 (1998) 437-441
16. Erion J.L., Bugaj J.E., Schmidt M.A., et al. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model. [abstract]. J Nucl Med 40 (1999) 223P
17. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
18. 111In-DTPA°]octreotide in patients. Eur J Nucl Med 28 (2001) 1319-1325
19. 3]octreotate. Eur J Nucl Med Mol Imaging 30 (2003) 417-422
20. 3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol 23 (2005) 2754-2762
21. Teunissen J.J., Kwekkeboom D.J., and Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA°,Tyr3]octreotate. J Clin Oncol 22 (2004) 2724-2729
22. Virgolini I., Britton K., Buscombe J., et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 32 (2002) 148-155
23. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 (2003) 2689-2696
24. Moertel C.G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1 (1983) 727-740
25. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303 (1980) 1189-1194
26. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
27. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 (1999) 944-948
28. Van Hazel G.A., Rubin J., and Moertel C.G. Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 67 (1983) 583-585
29. Bukowski R.M., Tangen C.M., Peterson R.F., et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73 (1994) 1505-1508
30. Ritzel U., Leonhardt U., Stockmann F., et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90 (1995) 627-631
31. Andreyev H.J., Scott-Mackie P., Cunningham D., et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13 (1995) 1486-1492
32. Neijt J.P., Lacave A.J., Splinter T.A., et al. Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer 71 (1995) 106-108
33. Ansell S.M., Pitot H.C., Burch P.A., et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 (2001) 1543-1548
34. O'Toole D., Hentic O., Corcos O., et al. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 Suppl 1 (2004) 79-84
35. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
36. Wong J.Y., Shibata S., Williams L.E., et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9 (2003) 5842-5852
37. Kong G., Lau E., Ramdave S., et al. High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. [abstract]. J Nucl Med 46 Suppl 2 (2005) 151P
38. Rich T.A., Shepard R.C., and Mosley S.T. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22 (2004) 2214-2232
39. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 (2002) 3983-3991